Seema Briyal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seema Briyal has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Anil Gulati
Chicago College of Pharmacy, Midwestern University, Downers Grove, IL 60515, USA
6 shared publications Anupama K. Puppala
1 shared publicationAnupama Puppala
1 shared publication- Bhagya Puppala
Department of Pediatrics, Division of Neonatology, Advocate Lutheran General Children's Hospital, Park Ridge, IL, USA; Advocate Medical Group, Park Ridge, IL, USA
1 shared publication - Imran Awan
Department of Pediatrics, Division of Neonatology, Advocate Lutheran General Children's Hospital, Park Ridge, IL, USA
1 shared publication Luu Thanh
1 shared publication
Latest Publications
- 1 December 2015
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 43, 5
19
- 1 February 2015
- Published by Elsevier in Brain and Development
- Vol. 37 (2) , 206-215
Ontogeny of endothelin receptors in the brain, heart, and kidneys of neonatal rats
- 1 February 2015
- Published by Elsevier in Brain and Development
- Vol. 37 (2) , 206-215
Ontogeny of endothelin receptors in the brain, heart, and kidneys of neonatal rats
- Open Access
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25) , e12
The Akt pathway mediates the neuroprotective effect of IRL-1620 in a rat model of focal cerebral ischemia
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25) , e12
Open AccessThe Akt pathway mediates the neuroprotective effect of IRL-1620 in a rat model of focal cerebral ischemia
- 1 December 2012
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 40 (12) , 1-328
190
We have demonstrated that stimulation of ETB receptors may enhance cerebral blood flow and provide neuroprotection; however, the mechanism of action of these receptors in cerebral ischemia has not been determined. Selective activation of ETB receptors by IRL-1620 may provide neuroprotection following cerebral ischemia by reducing oxidative stress and promoting angiogenesis. Cerebral ischemia was produced in male Sprague-Dawley rats by permanently occluding the middle cerebral artery. Animals were treated with either vehicle or IRL-1620 (5µg/kg, i.v.) at 2, 4 and 6 hours after occlusion. The role of ETB receptors was confirmed by treating rats with ETB antagonist, BQ788 (1 mg/kg, i.v.) and then administering vehicle or IRL-1620 following cerebral ischemia. After 24h, rats were assessed for neurological and motor deficit, and the brains were removed to determine the effects on infarct volume, oxidative stress, neuronal numbers and cerebral vasculature. Vehicle-treated rats presented with an infarct volume of 153.23 ± 32.18 mm3 along with marked neurological and motor deficit and a decrease in neuronal nuclei (PConclusions: Activation of ETB receptors via IRL-1620 reduced neurological damage, infarct volume, and oxidative stress, while increasing VEGF following cerebral ischemia in rats. These results demonstrate that selective ETB receptor activation may be a novel neuroprotective therapy in the treatment of cerebral ischemia.
- 1 December 2012
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 40 (12) , 1-328
190
We have demonstrated that stimulation of ETB receptors may enhance cerebral blood flow and provide neuroprotection; however, the mechanism of action of these receptors in cerebral ischemia has not been determined. Selective activation of ETB receptors by IRL-1620 may provide neuroprotection following cerebral ischemia by reducing oxidative stress and promoting angiogenesis. Cerebral ischemia was produced in male Sprague-Dawley rats by permanently occluding the middle cerebral artery. Animals were treated with either vehicle or IRL-1620 (5µg/kg, i.v.) at 2, 4 and 6 hours after occlusion. The role of ETB receptors was confirmed by treating rats with ETB antagonist, BQ788 (1 mg/kg, i.v.) and then administering vehicle or IRL-1620 following cerebral ischemia. After 24h, rats were assessed for neurological and motor deficit, and the brains were removed to determine the effects on infarct volume, oxidative stress, neuronal numbers and cerebral vasculature. Vehicle-treated rats presented with an infarct volume of 153.23 ± 32.18 mm3 along with marked neurological and motor deficit and a decrease in neuronal nuclei (PConclusions: Activation of ETB receptors via IRL-1620 reduced neurological damage, infarct volume, and oxidative stress, while increasing VEGF following cerebral ischemia in rats. These results demonstrate that selective ETB receptor activation may be a novel neuroprotective therapy in the treatment of cerebral ischemia.
- 26 November 2010
- Vol. 54 (2) , 99-122
Therapeutic potential of herbal drugs in cerebral ischemia.
Stroke is one of the most important causes of mortality and morbidity in the world. Prevention and effective treatment of stroke is of the utmost importance. Cerebral ischemia causes disturbances in a variety of cellular and molecular mechanisms, including oxidative phosphorylation, membrane function, neurotransmitter release, and free radical generation. It has been years since tissue-type plasminogen activator (t-PA) became the first medication approved by the FDA for the management of stroke, with limited success. Thrombolytic therapy is the most effective therapeutic strategy for the prevention of brain injury and reduction of mortality in patients with cerebral infarction. However, a combination of established thrombolytic therapy and effective neuronal protection therapy may have more beneficial effects for patients with cerebral infarction. Because clinical trials of pharmacological neuroprotective strategies in stroke have been disappointing, attention has turned towards approaches which include herbal drugs that can be used in limiting the neurological damage associated with stroke. Herbal drugs may be used as prophylactic treatment in patients with high risk of stroke. Herbals drugs have been described in ancient systems of medicine for the treatment of various ailments associated with stroke and have more recently been reported to be beneficial in treating stroke. However, the strength of evidence to support the use of these herbal drugs is unclear. This review focuses on putative mechanisms underlying the beneficial effects of herbal drugs in patients with stroke and on the possibility of herbal drugs to increase the therapeutic time window in patients with cerebral ischemia.
- 26 November 2010
- Vol. 54 (2) , 99-122
Therapeutic potential of herbal drugs in cerebral ischemia.
Stroke is one of the most important causes of mortality and morbidity in the world. Prevention and effective treatment of stroke is of the utmost importance. Cerebral ischemia causes disturbances in a variety of cellular and molecular mechanisms, including oxidative phosphorylation, membrane function, neurotransmitter release, and free radical generation. It has been years since tissue-type plasminogen activator (t-PA) became the first medication approved by the FDA for the management of stroke, with limited success. Thrombolytic therapy is the most effective therapeutic strategy for the prevention of brain injury and reduction of mortality in patients with cerebral infarction. However, a combination of established thrombolytic therapy and effective neuronal protection therapy may have more beneficial effects for patients with cerebral infarction. Because clinical trials of pharmacological neuroprotective strategies in stroke have been disappointing, attention has turned towards approaches which include herbal drugs that can be used in limiting the neurological damage associated with stroke. Herbal drugs may be used as prophylactic treatment in patients with high risk of stroke. Herbals drugs have been described in ancient systems of medicine for the treatment of various ailments associated with stroke and have more recently been reported to be beneficial in treating stroke. However, the strength of evidence to support the use of these herbal drugs is unclear. This review focuses on putative mechanisms underlying the beneficial effects of herbal drugs in patients with stroke and on the possibility of herbal drugs to increase the therapeutic time window in patients with cerebral ischemia.
- 10 October 2010
- Published by Elsevier in European Journal of Pharmacology
- Vol. 644 (1-3) , 73-79
Endothelin-A receptor antagonist BQ123 potentiates acetaminophen induced hypothermia and reduces infarction following focal cerebral ischemia in rats
- 10 October 2010
- Published by Elsevier in European Journal of Pharmacology
- Vol. 644 (1-3) , 73-79
Endothelin-A receptor antagonist BQ123 potentiates acetaminophen induced hypothermia and reduces infarction following focal cerebral ischemia in rats